How to Cite this Article: Stevenson DA, Carey JC, Byrne JLB, Srisukhumbowornchai S, Feldkamp M. 2012. Analysis of skeletal dysplasias in the Utah population. Am J Med Genet Part A. 158A:1046–1054.
Analysis of skeletal dysplasias in the Utah population†
Article first published online: 27 MAR 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part A
Volume 158A, Issue 5, pages 1046–1054, May 2012
How to Cite
Stevenson, D. A., Carey, J. C., Byrne, J. L.B., Srisukhumbowornchai, S. and Feldkamp, M. L. (2012), Analysis of skeletal dysplasias in the Utah population. Am. J. Med. Genet., 158A: 1046–1054. doi: 10.1002/ajmg.a.35327
- Issue published online: 18 APR 2012
- Article first published online: 27 MAR 2012
- Manuscript Accepted: 12 JAN 2012
- Manuscript Received: 2 NOV 2011
- Doris Duke Charitable Foundation Clinical Scientist Development Award
- Thrasher Research Fund
- skeletal dysplasia;
- birth outcomes
The Utah Birth Defect Network (UBDN) collects population-based data for Utah on births from all resident women. The prevalence of skeletal dysplasias and epidemiologic characteristics/outcomes were evaluated. Cases categorized as a skeletal dysplasia from all live births, stillbirths, and pregnancy terminations (TAB) between 1999 and 2008 were reviewed by three clinical geneticists. After case review, 153 were included for analysis (88% live births, 3% stillborn, 9% TAB), and categorized by groupings defined by molecular, biochemical, and/or radiographic criteria as outlined in the 2010 Nosology and Classification of Genetic Skeletal Disorders. The overall prevalence for skeletal dysplasias was 3.0 per 10,000 births, and 20.0 per 10,000 stillbirths. The most common diagnostic groups were osteogenesis imperfecta (OI; n = 40; 0.79 per 10,000), thanatophoric dysplasia (n = 22; 0.43 per 10,000), achondroplasia (n = 18; 0.35 per 10,000), and cleidocranial dysplasia (n = 6; 0.12 per 10,000). The most common groups based on the 2010 Nosology and Classification of Genetic Skeletal Disorders were the FGFR3 chondrodysplasia group (n = 41; 0.81 per 10,000), the OI/decreased bone density group (n = 40; 0.79 per 10,000), and the type 2 collagen group (n = 10; 0.2 per 10,000). Median age of postnatal diagnosis was 30 days (range 1–2,162). Of those deceased, 88% were prenatally suspected; of those alive 29% prenatally suspected. Median age of death for live born individuals was 1 day (range 1–1,450 days). Previously reported prevalence rates vary, but our data provide a population-based approach not limited to the perinatal/neonatal period. Understanding the range for survival within each group/diagnosis is beneficial for health care providers when counseling families. © 2012 Wiley Periodicals, Inc.